Previous Close | 35.90 |
Open | 48.30 |
Bid | 50.30 |
Ask | 57.80 |
Strike | 402.50 |
Expire Date | 2024-05-24 |
Day's Range | 48.30 - 48.30 |
Contract Range | N/A |
Volume | |
Open Interest | 1 |
On May 22, 2024, Bruce Sachs, Director at Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 7,073 shares of the company.
Cystic fibrosis treatment leader Vertex scored a breakout from a cup base this week, just a few weeks after an earnings beat.
On May 20, 2024, Reshma Kewalramani, CEO & President of Vertex Pharmaceuticals Inc (NASDAQ:VRTX), executed a sale of 15,202 shares of the company, according to the SEC Filing.